Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Immunohistochemical demonstration of CD20 in diffuse large B-cell lymphoma (DLBCL) is prerequisite not only for the diagnosis but also for assigning patients to rituximabcontaining chemotherapy. However, little is known about the impact of abundance of CD20 expression assessed by immunohistochemistry on the clinical outcome of DLBCL. We performed a semi-quantitative immunohistochemical analysis of CD20 expression in DLBCL to examine the prognostic implication of the level of CD20 expression. Methods: Pre-treatment diagnostic tissue samples from 48 DLBCL patients who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen were represented in a tissue microarray and immunostained for CD20. The relative abundance of CD20 expression was semi-quantitatively scored using a web-based ImmunoMembrane plug-in. Receiver operating characteristic curve analysis was used to determine a prognostically relevant cut-off score in order to dichotomize the patients into CD20-high versus CD20-low groups. Results: The levels of CD20 expression were heterogeneous among the patients, with a wide and linear distribution of scores. Patients in CD20-low group showed significantly poor clinical outcome. Conclusions: The levels of CD20 expression in DLBCL are heterogeneous among the patients with DLBCL. A subgroup of the patients with CD20 expression levels below the cut-off score showed poor clinical outcome.
Abstract
Background: Immunohistochemical demonstration of CD20 in diffuse large B-cell lymphoma (DLBCL) is prerequisite not only for the diagnosis but also for assigning patients to rituximabcontaining chemotherapy. However, little is known about the impact of abundance of CD20 expression assessed by immunohistochemistry on the clinical outcome of DLBCL. We performed a semi-quantitative immunohistochemical analysis of CD20 expression in DLBCL to examine the prognostic implication of the level of CD20 expression. Methods: Pre-treatment diagnostic tissue samples from 48 DLBCL patients who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen were represented in a tissue microarray and immunostained for CD20. The relative abundance of CD20 expression was semi-quantitatively scored using a web-based ImmunoMembrane plug-in. Receiver operating characteristic curve analysis was used to determine a prognostically relevant cut-off score in order to dichotomize the patients into CD20-high versus CD20-low groups. Results: The levels of CD20 expression were heterogeneous among the patients, with a wide and linear distribution of scores. Patients in CD20-low group showed significantly poor clinical outcome. Conclusions: The levels of CD20 expression in DLBCL are heterogeneous among the patients with DLBCL. A subgroup of the patients with CD20 expression levels below the cut-off score showed poor clinical outcome.
참고문헌 (22)
- Stein H, "WHO classification of tumours of haematopoietic and lymphoid tissues", pp.233~237 (2008), IARC Press
- Coiffier B, "State-of-the-art therapeutics: diffuse large B-cell lymphoma", J Clin Oncol, 23, pp.6387~6393 (2005)
- Boross P, "Mechanisms of action of CD20 antibodies", Am J Cancer Res, 2, pp.676~690 (2012)
- 김규호, "In-house Manual Construction of High-Density and High-Quality Tissue Microarrays by Using Homemade Recipient Agarose-Paraffin Blocks", Journal of Pathology and Translational Medicine, 47(3), pp.238~244 (2013), 대한병리학회[DOI]
- Berglund M, "Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis", Mod Pathol, 18, pp.1113~1120 (2005)
- Hans CP, "Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray", Blood, 103, pp.275~282 (2004)
- Tuominen VJ, "ImmunoMembrane: a publicly available web application for digital image analysis of HER2 immunohistochemistry", Histopathology, 60, pp.758~767 (2012)
- Salles G, "Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium", Blood, 117, pp.7070~7078 (2011)
- Culpin RE, "Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients", Histopathology, 63, pp.788~801 (2013)
- Coiffier B, "Rituximab therapy in malignant lymphoma", Oncogene, 26, pp.3603~3613 (2007)
- Mounier N, "Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)", Blood, 101, pp.4279~4284 (2003)
- Nyman H, "Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy", Blood, 109, pp.4930~4935 (2007)
- Winter JN, "Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP:a prospective correlative study", Blood, 107, pp.4207~4213 (2006)
- Sehn LH, "The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP", Blood, 109, pp.1857~1861 (2007)
- Johnson NA, "Diffuse large B-cell lymphoma:reduced CD20 expression is associated with an inferior survival", Blood, 113, pp.3773~3780 (2009)
- Olejniczak SH, "A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry", Immunol Invest, 35, pp.93~114 (2006)
- Horvat M, "Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma", Oncol Rep, 24, pp.1101~1107 (2010)
- Suzuki Y, "Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL", Ann Hematol, 91, pp.997~1005 (2012)
- Shimizu R, "HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells", Leukemia, 24, pp.1760~1768 (2010)
- Damm JK, "Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo", Exp Hematol Oncol, 4, pp.4~ (2015)
- Coiffier B, "Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia:a phase 1-2 study", Blood, 111, pp.1094~1100 (2008)
- Goede V, "Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions", N Engl J Med, 370, pp.1101~1110 (2014)